Anticomplement therapy in bullous pemphigoid.
Anticomplement therapy in bullous pemphigoid. Br J Dermatol. 2019 Jul 21;: Authors: Hashimoto T, Kanazawa N, Inoue N PMID: 31328264 [PubMed - as supplied by publisher]
Conclusions: We conclude that TSLP may activate DC-SIGN-positive DCs directly, which may be involved in the pathogenesis of BP. PMID: 33029540 [PubMed - in process]
Authors: Michelerio A, Tomasini CF Abstract Alzheimer's disease (AD) is characterized by a cluster of signs and symptoms manifesting with difficulties in memory, language disturbances, psychological and psychiatric changes and difficulty in carrying out daily activities. Although it may seem to be far from a dermatologic competence, the ageing of populations in industrialized and developing countries has changed things making AD a multidisciplinary question. Indeed, this neurodegenerative disorder is not exclusively neurological, but rather may involve multiple tissues and organs. The abnormalities in metabolic and...
ConclusionsDPP4i-associated BP is characterized by a more severe blistering and erosive presentation despite lower levels of typically pathogenic antibodies.
Extracellular vesicles (EVs), naturally secreted by almost all known cell types into extracellular space, can transfer their bioactive cargos of nucleic acids and proteins to recipient cells, mediating cell-cell communication. Thus, they participate in many pathogenic processes including immune regulation, cell proliferation and differentiation, cell death, angiogenesis, among others. Cumulative evidence has shown the important regulatory effects of EVs on the initiation and progression of inflammation, autoimmunity, and cancer. In dermatology, recent studies indicate that EVs play key immunomodulatory roles in inflammator...
Pregnancy may induce the onset or exacerbation of autoimmune bullous diseases such as pemphigus or pemphigoid gestationis. A shift toward T helper (Th) 2 immune response and the influence of hormonal changes have been evoked as possible triggering factors. Therapeutic management of this setting of patients may represent a challenge, mainly due to safety concerns of some immunosuppressive drugs during pregnancy and lactation. In this narrative review, we provided a comprehensive overview of the therapeutic management of autoimmune bullous diseases in pregnant and breastfeeding women, focusing on pemphigus and pemphigoid gestationis.
PMID: 32985676 [PubMed - as supplied by publisher]
PMID: 32981042 [PubMed - as supplied by publisher]
Condition: Bullous Pemphigoid Interventions: Drug: Avdoralimab (IPH5401); Other: Control Sponsor: Centre Hospitalier Universitaire de Nice Not yet recruiting
Publication date: Available online 23 September 2020Source: Actas Dermo-Sifiliográficas (English Edition)Author(s): O. Corral-Magaña, D. Morgado-Carrasco, X. Fustà-Novell, P. Iranzo
In this study we investigated whether patients with DH and CD (mean age for both 49 years) have circulating autoantibodies against BP180, the major BP autoantigen. ELISA tests showed that only a few DH (3/46) and CD (2/43) patients had BP180-NC16A IgG autoantibodies. Immunoblotting found that more than half of the DH samples contained IgG autoantibodies against full-length BP180. Epitope mapping with 13 fusion proteins covering the BP180 polypeptide revealed that in DH and CD patients, IgG autoantibodies did not target the NC16A or other epitopes typical of BP but recognized other intracellular and mid-extracellular region...